PRECISION MEDICINE PLATFORM
Precision Based Medical Technologies
We are revolutionizing healthcare in theranostics. Our purpose is to become the biopharmaceutical leader in the integration of traditional and alternative medicine. We develop therapeutic and diagnostic agents for identification, diagnosis, treatment, and monitoring treatment response.
WE LEAD THE WAY
Infectious Disease
Oncology. Neuroscience.
The Company holds rights to intellectual property including patents, patents-pending, and trademarks in the following sectors:
-
Diagnostic & Therapeutic Imaging/Treatment Platform
VB’s technology integrates diagnostics and therapeutics for image-guided therapy that defines the treatment outcome at an early stage. Our technology transforms the patient experience from the initial diagnosis. Our technology brings precision imaging to both traditional medicine and agribiopharmaceuticals. Our focus is to make meaningful advancements in diverse therapeutic areas. Theranostics provides a cost-effective and efficient transition to predictive and personalized medicine.
VB’s replicable and scalable methods and processes will take a compound through the completion of Phase Zero. This establishes the opportunity for global pharmaceutical companies to execute long-term licensing agreements with VB. This partnership utilizes VB’s theranostic technology to advance drug development through Phase I, II, and III human trials, expediting the process to regulatory approval and commercialization.
-
Diagnostic & Therapeutic Imaging/Treatment Platform
VB’s technology integrates diagnostics and therapeutics for image-guided therapy that defines the treatment outcome at an early stage. Our technology transforms the patient experience from the initial diagnosis. Our technology brings precision imaging to both traditional medicine and Agribiopharmaceuticals. Our focus is to address infectious diseases, certain forms of cancer, epilepsy, PTSD, and other neurodegenerative disorders.
VB’s replicable and scalable methods and processes will take a compound through the completion of Phase Zero. This establishes the opportunity for global pharmaceutical companies to execute long-term licensing agreements with VB. This partnership utilizes VB’s theranostic technology to advance drug development through Phase I, II, and III human trials, expediting the process to regulatory approval and commercialization.